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Aims: This study explores how well the World Health Organization Disability Assessment
Schedule (WHODAS 2.0) assesses problems with psychosocial functioning in patients
with severe mental illness (SMI). Further, we assessed the relationships between
psychosocial functioning and psychopathology, medication side effects, treatment
setting, and quality of life.
Methods: We performed an observational, cross-sectional study on the island of
Curaçao to assess psychosocial functioning in 77 patients with SMI; they mainly had
psychotic disorders. We interviewed their healthcare providers using the proxy version of
the WHODAS 2.0. In addition, patients were examined for psychiatric symptoms,
medication side effects (including drug-induced movement disorders), and quality of life.
Associations were examined with Spearman's rank correlation (r).
Results: Difficulties in psychosocial functioning were reported by patients with SMI in the
WHODAS 2.0 domains of understanding and communicating [mean (M)=34.5, standard
deviation (SD)=18.6), participation in society (M=25.5, SD=15.6), and getting along with
people (M=24.1, SD=16.1)]. Notably, outpatients had more problems participating in
society than inpatients (M=33.6, SD=18.5 versus M=23.2, SD=14.1, p=0.03). A positive
correlation was observed between drug-induced parkinsonism and the WHODAS 2.0
total score (r =0.30; p=0.02), as well as with various subscales, getting around, and
household activities.
Conclusion: The proxy version of the WHODAS 2.0 is clinically useful for patients with
severe mental illness. The highest scores on the WHODAS 2.0 were found in domains
related to interactions with other people and to participation in society. Inpatient status
appeared to aid participation in society; this might be due to living in the sheltered clinicg April 2020 | Volume 11 | Article 3031
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Frontiers in Psychiatry | www.frontiersin.orenvironment and its associated daily activities. We further found that drug-induced
parkinsonism was associated with a broad spectrum of psychosocial disabilities.
Clinical Trial Registration: ClinicalTrials.gov, identifier: NCT02713672; retrospectively
registered in February 2016Keywords: WHO Disability Assessment Schedule, severe mental illness, functioning, schizophrenia, Caribbean,
recovery, rehabilitationINTRODUCTION
The term “severe mental illness” (SMI) was introduced by the
USA Substance Abuse and Mental Health Services
Administration to differentiate between psychiatric patients
with and without problems in daily functioning. Criteria for
SMI include excessive disturbance and clinically significant
distress or impairment in social, occupational, or other
important areas of functioning. Although, potentially, all
Diagnostic and Statistical Manual of Mental Disorders, 5th
Edition (DSM-5), diagnoses can be involved, most of the
patients who qualify as severely mentally ill have been
diagnosed with schizophrenia, or another psychotic or major
mood disorder. The prevalence of severe mental illness in the
USA is about 5% in adults (1).
In the aim of treatment of patients with SMI, there is
currently a shift in focus from care to recovery. Recovery is a
process in which the most important goal is to regain a
meaningful life in the community, including participation in
valued activities and fulfillment of social roles (2–5).
Participation in everyday activities, such as occupational or
educational activities, coupled with adequate social
functioning, are considered important indicators of recovery
(3, 6). Central to the monitoring of the recovery process is the
measurement of patients' psychosocial functioning.
In DSM-5, the World Health Organization Disability
Assessment Schedule (WHODAS 2.0) was introduced as a
better measure of psychosocial functioning in individuals with
psychiatric disorders (7) than the earlier Global Assessment of
Functioning (GAF). The WHODAS 2.0 was explicitly designed
to exclude items on pathology to avoid confounding symptoms
and functioning, which is a core problem with the GAF (8).
Impaired psychosocial functioning in patients with SMI is
multifactorial: adverse medication reactions (parkinsonism,
obesity), and treatment setting (in- or outpatient) may
influence functional recovery (9–13). For example, the
medication side effect parkinsonism is associated with poor
vocational performance (11), while some studies show positive
results for community-based rehabilitation versus in-hospital
treatment in patients with SMI (12–14).
The WHODAS 2.0 offered valuable insight into patients'
experiences, had acceptable validity and psychometric
properties, but it was challenging to use with patients with
long-term psychotic disorders and several limitations were
reported (15, 16), e.g., caregivers generally reported worse
functioning than patients themselves. A lack of insight (i.e.,g 2awareness of their illness and its consequences) in patients
with SMI meant they registered fewer difficulties than expected
in the questionnaire (15–17). Researchers also had to try hard to
keep such patients focused on answering the questions, possibly
because they had cognitive deficits (15). Using the proxy version
of the WHODAS 2.0 could parry these limitations, since the
interview is done with the patient's healthcare professional or a
family member. Yet, to our knowledge, there are only a few
publications about using it for patients with severe (neuro)
psychiatric disorders (17–19). One study, in Ethiopia in
patients with SMI, found that the proxy version had acceptable
validity and psychometric properties, but higher mean values
and better responsiveness to change than the patient interview
version (17).
Our study explored the use of the proxy version of the
WHODAS 2.0 for assessing psychosocial functioning in a
population with SMI. Further, we assessed the relationships
between functioning and psychopathology, medication side
effects, treatment setting, and quality of life.METHODS
Our study was performed in the well-defined geographical area
of Curaçao, an island in the Caribbean and part of the former
Dutch Antilles. The study was also part of a clinical trial on
CYP2D6 and CYP2C19 genotyping in patients with SMI (20).
Our study population of 77 patients with SMI was part of the
Curaçao Extrapyramidal Syndromes studies cohort (I-XIII) (21,
22). AK, DV, PH, and HH have worked as medical doctors
on Curaçao.
Our participants were inpatients recruited in November–
December 2014 from the Klinika Capriles (the only psychiatric
hospital on the island) and from the psychiatric ward of the
prison, and outpatients recruited from the psychiatric outpatient
clinic (Psychiaters Maatschap Antillen).
Inclusion criteria for the study were: 1) Antillean ethnicity,
defined according to the Dutch Central Bureau of Statistics as
born on the former Netherlands Antilles, with at least one parent
also born on the former Netherlands Antilles; 2) aged 18 years or
older, and 3) meeting SMI criteria, defined as having a mental
disorder causing functional impairment as shown by the need for
intensive psychiatric care in or out of hospital. Exclusion criteria
were: 1) refusal to give written informed consent, or 2) no family
member or healthcare professional available and willing to
participate in the study.April 2020 | Volume 11 | Article 303
Koopmans et al. WHODAS 2.0 in Severe Mental IllnessWe approached 86 patients, of whom 77 (90%; 30 females, 47
males) met our inclusion criteria. Eight patients were excluded
because they had no healthcare professional or family member
available for interview; one patient died before inclusion. After
being informed about the study procedures, all patients signed an
informed consent form.
Of the 77 proxy questionnaires, two were completed by family
members and 75 by healthcare professionals. The healthcare
professionals were all nurses, with patient contact at least once
a week.
Measurements
Each patient had a thorough assessment of psychopathology,
subjective experience, extrapyramidal symptoms, quality of life,
and global functioning. Demographic information was
registered. In line with a previous study on SMI patients on
Curaçao (21), diagnosis was based on clinical diagnoses as
registered by the treating psychiatrist and documented in the
participating patients' health records. The healthcare system on
Curaçao meets Western standards and the majority of medical
specialists are trained in the Netherlands. Information on
psychiatric and somatic medication was derived from the
electronic patient file. Until recently, Dutch was the only
official language on Curaçao and we were able to communicate
in Dutch with all healthcare professionals and family members.
However, not all our study participants had completed secondary
school education, and for those who did not understand Dutch
(32 out of 77 patients), we communicated in the local language,
Papiamentu, with the help of a bilingual hospital resident-in-
psychiatry. To prevent outcome effects because of inter-rater
variability, all measurements were done by the same investigator
(AK). To prevent halo effects, the nurses were interviewed for the
WHODAS with the interviewer blinded to the patient concerned.
In this way we could ensure that there was no clinical prejudice
in the way the interviewer scored the WHODAS items.
Functioning
Functioning was measured using the official Dutch translation of
the proxy interview version of the WHODAS 2.0 (32 items),
which was used with well-informed healthcare professionals or
family members (23). Ideally we would also have used the patient
version of the WHODAS 2.0 to provide information on the
relationship between the two versions of the scale. This
information would have helped to strengthen the rationale to
use the proxy version of the scale. Previous studies have reported
that patients with schizophrenia and schizoaffective disorders are
poor raters of their level of functioning but good raters of other
characteristics such as quality of life (24–26). Higher levels of
depressive symptoms are associated with underestimations in
self-reports, while delusions and suspiciousness are associated
with overestimation of functioning compared to interviewer
judgments (27, 28). In addition, co-authors DH and HH
cooperated in the World Health Organization's (WHO)
development of the WHODAS 2.0 and concluded that the
patient version was difficult to administer to patients with
schizophrenia (29). Also, in a small pilot study, first author AK
tested this questionnaire. She found that concentration problemsFrontiers in Psychiatry | www.frontiersin.org 3hampered the completion of the WHODAS 2.0 questionnaire,
possibly due to its length (36 items) and the complex wording of
some of the items. These concentration problems negatively
affected the reliability of the answers and prompted our use of
the informant version. Furthermore, almost none of the patients
in the pilot and current study had completed secondary school,
which may also explain the difficulties observed in the pilot
patients when completing the WHODAS 2.0. Their low level of
education may have resulted in problems in answering the
complex questions. These observations supported our use of
the informant version.
The questionnaire measures patients' functioning in six
domains: 1) understanding and communicating (six items), 2)
getting around (five items), 3) self-care (four items), 4) getting
along with people (five items), 5) work and household activities
(each four items), and 6) participation in society (eight items).
Four items on work were not included in our study because
almost none of the participants had a job—this is in line with the
instructions in the Manual for WHO Disability Assessment
Schedule WHODAS 2.0 (30).
Standardized summary scores range from 0 to 100, with
higher scores indicating greater levels of disability in
functioning (30).
The patient interview version of WHODAS has a robust
factor structure that is replicated across countries and
populations, has high internal consistency (Cronbach's a
coefficient of 0.96 for its 36 items, good test-retest reliability
(intraclass correlation coefficient of 0.98), good concurrent
validity with other quality of life and handicap scales
(correlation coefficients 0.45–0.65), and a reasonable
sensitivity to change (effect sizes 0.44–1.38) (31, 32). In the
general population 90% has a total score of 35 or lower,
indicating little or no disability in functioning (30). The
proxy interview version shows good internal consistency
(0.82–0.99) and good convergent validity in patients with
severe mental disorders (17). It has a moderate sensitivity to
change (0.14–0.57), which is nonetheless more sensitive than
the patient version in this specific (SMI) population (0.17–
0.35) (17).
The interviewer, a resident-in-psychiatry (AK), was trained
by experts (DH and HH) in scoring the WHODAS 2.0.
Symptom Severity and Side Effects
The severity of patients' psychopathology was assessed with the
Brief Psychiatric Rating Scale (BPRS; 24 items). This rating scale
has five subscales: affect (anxiety, guilt, depression, somatic);
positive symptoms (thought content, conceptual disorganization,
hallucinatory behavior, grandiosity); negative symptoms
(blunted affect, emotional withdrawal, motor retardation);
resistance (hostility, uncooperativeness, suspiciousness); and
activation (excitement, tension, mannerisms–posturing) (33–
35). Extrapyramidal side effects were assessed with the St. Hans
Rating Scale (SHRS), a multidimensional rating scale for the
evaluation of dyskinesia (18 items), parkinsonism (10 items), and
dystonia (2 items) induced by antipsychotics. The dyskinesia is
scored in two situations: in passive and active circumstances (36).
Akathisia, a movement disorder and medication side effect, wasApril 2020 | Volume 11 | Article 303
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induced akathisia (BARS; three items) (37, 38).
For all the above scales, higher scores indicate more severe
symptoms. AK, a resident-in-psychiatry, was the interviewer for
all the scales; she was trained by experts in scoring the SHRS and
BARS (PH and HH), and this included a training course with 10
Antillean patients with SMI on Curaçao.
Patient experience of psychopharmacological medication side
effects was measured with the Subjective Well-Being Under
Neuroleptics Scale (SWN-20; 20 items). This is a self-rating
scale that assesses subjective experience over the preceding
seven days (39). For patients who were unable to read Dutch,
the SWN-20 questions were translated into Papiamentu. Scores of
negative statements were recoded to indicate that higher scores on
all statements reflected higher levels of well-being. Drug-induced
weight gain was measured using body mass index (BMI).
Quality of Life
Quality of life was assessed with the EQol 5D (EQ-5D; five
items), a widely-used scale that measures health status on five
dimensions: 1) mobility, 2) self-care, 3) daily activities, 4) pain/
discomfort, and 5) anxiety/depression (40, 41). Higher scores
indicate a lower quality of life. The EQ-5D shows some overlap
with several WHODAS 2.0 domains, including getting around,
self-care, and work and household activities.
Statistics
All analyses were performed with IBM SPSS Statistics Version
25. Normality of the data distribution for all measurements was
assessed by inspecting Q-Q plots. We conducted multiple
regression analyses to identify how much age and gender
contributed independently to the WHODAS 2.0 outcomes. The
Mann-Whitney U test was used to compare outcomes between
in- and outpatients. Correlations between the WHODAS 2.0 and
the other measures were examined using Spearman's rank
correlation (r), with the significance level set at p < 0.05.Frontiers in Psychiatry | www.frontiersin.org 4RESULTS
Patient Characteristics
Eighteen (23.4%) patients were outpatients and 59 (76.6%) were
inpatients. The inpatients lived in housing on the clinic site and
had been there for at least 2.5 years. Of those included in the
study, 95% had a diagnosis of a psychotic disorder. Other
diagnoses included depression, bipolar disorder, substance
abuse, and intellectual disability. All patients were using
antipsychotic medication [of these, 40 (52%) used biperidene
and 45 (58%) were prescribed two types of antipsychotics].
Antidepressant medication was prescribed for 7 (9%) of the
patients, while 8 (10%) were using anti-epileptic medication and
33 (42%) were using cardiovascular medication.
Distribution of Total and Domain Scores
of Functioning
The WHODAS 2.0 mean standardized domain and total scores
are shown in Table 1. The mean total score of the 32-item
WHODAS 2.0 scale was 31.2 (SD=16.5) with a minimum score
of 2.5 and a maximum score of 78.9. Twenty percent of patients
had a total score ≥ 35, which falls above the 90th percentile of
overall disability in functioning according to general population
data for the WHODAS 2.0 interview version (30).
Multiple regression analyses showed no difference in the
distribution of WHODAS 2.0 scores according to age or gender.
Re-analysis of the outcomes, excluding the two questionnaires
filled out by family members, did not change the results.
Functioning and Psychopathology
The correlations between psychopathological symptoms as
measured by the BPRS and WHODAS 2.0 scores are shown in
Table 2.
Functioning and Medication Side Effects
The correlations between SHRS, BARS, SWN-20, and BMI
scores with WHODAS 2.0 scores are shown in Table 2. TheTABLE 1 | Patient characteristics and mean standardized WHO Disability Assessment Schedule (WHODAS) 2.0 scores of in- and outpatients with severe mental illness.
Measurements Total Inpatients Outpatients Mann Whitney-U
N Mean SD N Mean SD N Mean SD U p-value
Age in years 51.4 11.4 52.4 48.2 404.5 .128
Female (%) 38.9 39.0 38.9 .994#
WHODAS 2.0 domains
Understanding and communicating 77 34.5 18.6 59 35.3 18.0 18 31.9 20.8 470 .46
Getting around 77 14.1 18.6 59 13.2 18.1 18 17.0 20.4 465 .41
Self-care 77 9.0 11.1 59 8.9 11.5 18 9.0 10.1 510 .79
Getting along with people 69 24.1 16.1 55 23.4 16.2 14 26.8 16.2 327.5 .39
Household activities 75 18.5 21.0 59 17.1 20.6 16 23.8 22.4 389.5 .27
Participation in society 74 25.5 15.6 58 23.2 14.1 16 33.6 18.5 292.5 .02*
Total score† 66 31.2 16.5 54 29.6 15.5 12 38.3 19.6 223.0 .09April 2020 | Volume 11 | Article 30SMI, severe mental illness; WHODAS, World Health Organization Disability Assessment Schedule, † standardized total score of the 32-item scale (exclusion of work items), #chi square,
* significant at the.05 level, N number of patients, SD standard deviation3
Koopmans et al. WHODAS 2.0 in Severe Mental Illnessresults indicate that a higher level of drug-induced parkinsonism
was associated with more problems in functioning in the areas
understanding and communicating, getting around, and
household activities.
Higher well-being under neuroleptics is associated with better
functioning in the domain of understanding and communicating.
Functioning and Quality of Life
The correlations between the EQ-5D and WHODAS 2.0 scores
are shown in Table 2. A higher WHODAS 2.0 score (worse
global functioning) is associated with a higher EQ-5D score
(lower quality of life).DISCUSSION
This study is one of the first to examine WHODAS 2.0 proxy
scores of psychosocial functioning in patients with SMI. Our
results show that symptom severity and medication side effects
have a negative association with functioning, quality of life, and
subjective well-being in patients with SMI. They also recorded
the highest scores on WHODAS 2.0 domains related to
interactions with other people and participating in society,
revealing their greater psychosocial disabilities in these areas.
These results are consistent with earlier findings, in which
psychotic patients reported problems with community
activities and experienced barriers in their environment (15).
Psychopathology
The correlation between psychopathology symptoms and
participation in society confirms earlier findings in SMIFrontiers in Psychiatry | www.frontiersin.org 5popula t ions , in which pat ients wi th more severe
psychopathology reported more difficulties in functioning on
the WHODAS 2.0 (12- and 36-item versions), whereas patients
with fewer mental health problems reported better scores for
recovery (17, 18, 42). We did not find a significant correlation
between psychosocial functioning and positive symptoms; this is
in agreement with an earlier study in patients with
schizophrenia, which found no relationship between positive
symptoms and social network size (43). It suggests that the
primary focus of traditional treatment on symptoms like
hallucinations and thought disorders is not necessarily
associated with better functioning.
Treatment Setting
In contrast to our expectations, outpatients reported more
problems with participation in society than inpatients. This
contrasts with results from a previous validation study of
pat ients with schizophrenia , in which outpat ients
demonstrated better social functioning than inpatients, as rated
by independent assessors (44). There are several possible
explanations: first, inpatients may have better participatory
skills than outpatients. This seems unlikely however, because
their psychopathology symptoms did not differ. Another
explanation stems from healthcare professionals perhaps
having different frames of reference for in- and outpatients and
their participation in society. For outpatients they may have
other insights into barriers for functioning (e.g., stigmatization)
in society. It is possible that long- and short-term inpatients and
their healthcare professionals are accustomed to the status quo
and have lower expectations of life than outpatients (and their
healthcare professionals) who are constantly confronted with
















Number of patients 77 77 77 69 75 74 66
BPRS: 24 items (1–7)
Affective symptoms .19 .21 .14 .06 .16 .23 .21
Positive symptoms .14 .05 .16 −.12 .24 .10 .14
Negative symptoms .28* .24* .27* .10 .14 .09 .29*
Resistance .09 .01 .01 .21 .04 .28* .18
Activation .02 −.19 −.07 .01 −.19 .10 −.05
Total score 29* .21 .23 .06 .20 .35** .34**
SHRS: 30 items (0–6)
Dyskinesia .15 −.13 .02 −.22 −.06 −.16 −.13
Parkinsonism .24* .37** .16 .10 .23* .11 .30*
Dystonia .05 .01 −.18 .02 .10 .11 .05
Acathisia .02 −.07 −.13 .01 −.12 .12 −.04
BARS: 3 items (0–3) .01 −.09 −.14 .01 −.11 .12 −.06
SWN-20: 20 items (1–6) −.27* −.13 −.08 −.11 −.10 −.22 −.24
BMI −.16 .07 .05 −.03 −.12 −.02 −.08
EQ-5D: 5 items (1–3) .22 .39** .10 −.01 .20 .26* .33*April 2020 | Volume 11 |SMI, severe mental illness; WHODAS, World Health Organization Disability Assessment Schedule; BPRS, Brief Psychiatric Rating Scale; SHRS, St. Hans Rating Scale; BARS, Barnes
Akathisia Rating Scale for drug-induced akathisia; EQ-5D, EQol 5-D; SWN-20, Subjective Well-Being Under Neuroleptics Scale; BMI, body mass index, †standardized total score of the 32
item scale (exclusion of work items), * significant at.05 level, ** significant at.01 levelArticle 303
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is that participation is easier in the sheltered environment of an
inpatient setting, in which co-citizens also have severe mental
disorders, and where social activities are organized, patients are
encouraged to participate in activities, basic life needs are taken
care of, and barriers and problems are partly resolved
by caregivers.Medication Side Effects
There was a significant correlation between drug-induced
parkinsonism and problems in getting around and performing
household activities. This could be related to the symptoms of
drug-induced parkinsonism such as tremor, bradykinesia,
rigidity, and postural instability (45). These motor symptoms
can directly influence walking pattern and daily household tasks
(46, 47). In addition, there was a significant correlation between
parkinsonism and understanding and communicating. This is in
line with earlier reports about the non-motor signs of drug-
induced parkinsonism e.g., cognitive dysfunction, apathy, and
mood disorders (48–50). Hence, drug-induced parkinsonism
appears to be associated with a broad spectrum of dysfunction
and may be a barrier to recovery.Strengths and Limitations
We studied a difficult-to-examine population of severely ill
psychiatric patients who were recruited from all three
psychiatric institutions on Curaçao. There was no selection
regarding the type of psychiatric care or medication, presence
of side effects, or treatment response when the participants were
recruited. This resulted in a group of patients who are
representative of the general population with SMI on Curaçao.
Although nearly half of our participants were unable to
communicate in Dutch, we were able to use the official Dutch
translation of the WHODAS 2.0, as all the healthcare
professionals are educated in Dutch. So far, no local-language
versions of the WHODAS 2.0 are available for populations in the
Caribbean who do not speak English or Dutch. Although it
would have been valuable to interview a relative, most of the
patients did not have an engaged relative. A personal healthcare
provider who was engaged with all the patient's personal
activities was interviewed instead. In a previous study assessing
patient functioning, it was found that high-contact clinicians
generated ratings of everyday functioning that were more closely
linked to patients' ability scores than those from friends or
relatives (51).
Not all patients were able to read the Dutch language. To be
able to administer the SWN-20 self-report questionnaire to these
patients, it was translated by a bilingual (Papiamentu-Dutch)
resident-in-psychiatry. No back translation was performed and
we did not formally ensure whether the validity and reliability of
the questionnaire were still intact. Failure to complete back
translation of the SWN-20 might have affected the reliability
and validity of the data from the questionnaire and its
subsequent correlation with the WHODAS 2.0 and itsFrontiers in Psychiatry | www.frontiersin.org 6domains. Our examination of the correlation between the
WHODAS 2.0 and its domains and the SWN-20 in the subset
of patients who completed the Dutch version of the scale (n=38)
showed similar results to those on the subset that completed the
translated version of the SWN-20 (n=39). This indicates that the
negative impact of the failure to back translate was minimal.
Problems with using questionnaires on functioning with
patients with poor insight and cognitive deficits, as reported in
earlier studies and confirmed in a pilot study, were parried by
using the proxy-version with well-informed third parties. A
limitation of this study is that we did not interview the
patients themselves using the WHODAS 2.0, because a pilot
study with the patient version of the questionnaire showed that
patients' concentration problems negatively affected the
reliability of their answers. Therefore we could not compare
the information given by patients with that from their proxies.
Responder bias (judgment differences between healthcare
professionals attending inpatients vs. outpatients) could not be
ruled out, however, the results indicate that useful information
on psychosocial functioning can be retrieved from proxies.
Lastly, both the small sample size and the non-normal
distribution of our data, requiring non-parametric tests, are
challenges for the power of our analyses, and thus the strength
of our findings. Non-parametric tests (here: Spearman rho and
Mann Whitney) have less statistical power than their
parametrical equivalents. As our main purpose was to explore
relationships between different measures, we chose to show all
individual results of our small sample size study. Thus, together
with the fact that the study has a cross-sectional design, the
results need to be treated with caution. Future studies, using
larger sample sizes are needed to confirm our findings.CONCLUSIONS
In this exploratory study, we show that the proxy version of the
WHODAS 2.0 is a clinically useful instrument for patients with
severe mental illness and that it provides good insight into the
psychosocial functioning of these patients. In patients with lack
of insight into their disease or severe cognitive deficits, this proxy
questionnaire version can be used to determine useful
information about patients' problems in psychosocial
functioning. The highest scores on the WHODAS 2.0 (i.e.,
indicating the greatest difficulties in functioning) were found in
domains related to interactions with other people and
participation in society. Inpatients were reported to experience
fewer problems with participation in society than outpatients,
which could be due to the adapted circumstances and sheltered
environment of the clinic. We found drug-induced parkinsonism
is associated with a broad spectrum of social disabilities. Before
any practice or policy recommendations can be made, our results
need to be replicated, preferably with larger samples. Wherever
possible, researchers should include the patient interview version
of the WHODAS 2.0 in order to compare the outcomes of the
two versions of the questionnaire.April 2020 | Volume 11 | Article 303
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